Patents by Inventor Maria Del Monte Millan

Maria Del Monte Millan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200371107
    Abstract: A method and system for detecting, manipulating and isolating circulating tumor cells found in organic fluids comprising a simplified laser assisted transfer process. A liquid specimen of the organic fluid containing an enriched population of tumor cells and a population of non-tumor cells is spread onto a donor substrate with an interlayer comprising a semi-transparent polymeric adhesive tape. A fluorescent staining of at least one of the cell populations present in the liquid specimen is required to identify-using optical and fluorescence microscopy, the location of the cells to be manipulated and/or isolated. The laser beam energy is absorbed by the polymeric adhesive tape giving place to the formation of a blister that mechanically interacts with the liquid specimen and such interaction can induce the expulsion of a portion of the liquid specimen comprising the selected tumor cells or non-tumor cells, which can be a single cell or a cell cluster, towards the receiving substrate.
    Type: Application
    Filed: January 29, 2018
    Publication date: November 26, 2020
    Applicant: FUNDACIÓN PARA LA INVESTIGACIÓN BIOMÉDICA DEL HOSPITAL GREGORIO MARAÑÓN
    Inventors: Carlos Luis MOLPECERES ÁLVAREZ, Sara LAUZURICA SANTIAGO, Andrés MÁRQUEZ FERNÁNDEZ, David MUÑOZ MARTÍN, Miguel MORALES FURIÓ, Mónica COLINA BRITO, MARTÍN JIMÉNEZ, Miguel, Rocío RAMOS MEDINA, Andrés MUÑOZ MARTÍN, Javier GAYARRE NAVARRO, Tatiana MASSARRAH SÁNCHEZ, María DEL MONTE MILLÁN
  • Publication number: 20110144148
    Abstract: The invention provides compounds of formula: which have a tacrine moiety connected to an heterocyclic moiety through a linker. Through careful selection of the substituents and the linker, the activity and selectivity towards acetylcholinesterase can be modulated. The compounds show potent AChE inhibition activities together with modifications in the ?-amyloid aggregation properties by binding simultaneously to the catalytic and peripheral AChE sites. They are useful in the treatment of AChE mediated diseases, such as the Alzheimer's disease.
    Type: Application
    Filed: February 18, 2011
    Publication date: June 16, 2011
    Applicant: NOSCIRA, S.A.
    Inventors: Ana Martinez Gil, Isabel Dorronsoro Diaz, Laura Rubio Arrieta, Diana Alonso Gordillo, Ana Fuertes Huerta, Susana Morales-Alcelay, Maria Del Monte Millan, Esther Garcia Palomero, Paola Usan Egea, Celia De Austria, Miguel Medina Padilla, Pilar Munoz Ruiz
  • Patent number: 7910739
    Abstract: The invention provides compounds of formula: which have a tacrine moiety connected to an heterocyclic moiety through a linker. Through careful selection of the substituents and the linker, the activity and selectivity towards acetylcholinesterase can be modulated. The compounds show potent AChE inhibition activities together with modifications in the ?-amyloid aggregation properties by binding simultaneously to the catalytic and peripheral AChE sites. They are useful in the treatment of AChE mediated diseases, such as the Alzheimer's disease.
    Type: Grant
    Filed: July 9, 2004
    Date of Patent: March 22, 2011
    Assignee: Noscira, S.A.
    Inventors: Ana Martinez Gil, Isabel Dorronsoro Diaz, Laura Rubio Arrieta, Diana Alonso Gordillo, Ana Fuertes Huerta, Susana Morales-Alcelay, Maria Del Monte Millan, Esther Garcia Palomero, Paola Usan Egea, Celia De Austria, Miguel Medina Padilla, Pilar Munoz Ruiz
  • Publication number: 20090221647
    Abstract: The present invention relates to the use of N-(2-thiazolyl)-amide derivatives of formula (I), for the treatment and/or prophylaxis of a disease in which glycogen synthase kinase 3 (GSK-3) is involved, especially neurodegenerative diseases, such as Alzheimer's disease, or non-insulin dependent diabetes mellitus.
    Type: Application
    Filed: April 27, 2007
    Publication date: September 3, 2009
    Applicant: NOSCIRA, S.A.
    Inventors: Ana Martinez Gil, Ana Castro Morera, Miguel Medina Padilla, Ester Martin Aparicio, Mercedes Alonso Cascon, Ana Fuertes Huerta, Maria Luisa Navarro Rico, Maria Jose Perez Puerto, Maria Del Monte Millan
  • Publication number: 20090192204
    Abstract: The present invention relates to the use of N-(2-thiazolyl)-amide derivatives of formula (I) for the treatment and/or prophylaxis of a disease in which glycogen synthase kinase 3 (GSK-3) is involved, especially neurodegenerative diseases, such as Alzheimer's disease, or non-insulin dependent diabetes mellitus.
    Type: Application
    Filed: April 27, 2007
    Publication date: July 30, 2009
    Applicant: NOSCIRA, S.A.
    Inventors: Ana Martinez Gil, Ana Castro Morera, Miguel Medina Padilla, Ester Martin Aparicio, Mercedes Alonso Cascon, Ana Fuertes Huerta, Maria Luisa Navarro Rico, Maria Jose Perez Puerto, Maria Del Monte Millan
  • Publication number: 20080119521
    Abstract: The invention provides butyrylcholinesterase inhibitors of formula (I), which contain an heterocyclic moiety and a 4 piperidine moiety with a linker in between. The compounds show a very high activity and selectivity towards BuChE, making them useful for the treatment and/or prophylaxis of cognitive disorders and/or neurodegenerative disorders.
    Type: Application
    Filed: May 27, 2005
    Publication date: May 22, 2008
    Inventors: Ana Martinez Gil, Laura Rubio Arrieta, Pilar Muñoz Ruiz, Isabel Dorronsoro Diaz, Esther Garcia Palomero, Maria del Monte Millan, Miguel Medina Padilla
  • Publication number: 20080039513
    Abstract: The invention provides compounds having a spiro heterocyclic unit connected through a linker of a certain length to another spiro cycle, an imidazole ring or an amide group. Some of these compounds have been obtained from Aplysinia cavernicola and a mixture of Aplysina fulva and Oceanapia. The compounds exhibit VDCC blocker activity; some also show acetylcholinesterase and butyrylcholinesterase inhibition activities. Therefore they are useful in the treatment of cognitive and neurodegenerative disorders, such as brain ischemia, stroke, cognitive disorders as senile dementia, cerebrovascular dementia, mild recognition impairment, attention deficit disorder, and/or neurodegenerative dementing disease with aberrant protein aggregations as specially Alzheimers's disease or condition, or prion disease as Creutzfeld-Jakob disease or Gerstmann-Straussler-Scheinker disease.
    Type: Application
    Filed: June 17, 2005
    Publication date: February 14, 2008
    Inventors: Ana Martinez Gil, Diana Alonso Gordillo, Isabel Dorronsoro Diaz, Esther Garcia Palomero, Celia De Austria De Luque, Paola Usan Egea, Maria Del Monte Millan, Miguel Medina Padilla